Related Experiment Video
Updated: Jan 22, 2026
Novel Mini-open Transforaminal Lumbar Interbody Fusion
Published on: June 6, 2025
Analysis of Procedural Costs and Outcomes Between Autograft, BMP-2, and Viable Cellular Allograft in Lumbar Interbody
Thomas Giannasca1, Michael Mancini2, Jake Laverdiere1
1Frank H. Netter MD School of Medicine, Quinnipiac University, Hamden, CT.
Study Design/Setting:
Retrospective, multisurgeon cohort at a single academic center with ≥2-year follow-up.
Objective:
To identify dominant, modifiable drivers of intraoperative cost in lumbar interbody fusion and evaluate outcome profiles between graft types.
Summary Of Background Data:
Instrumentation and biologics are major cost contributors in lumbar fusion, yet prior reports often aggregate spending into broad categories, obscuring which specific supply decisions drive expenditure. Biologics such as bone morphogenic protein (BMP) and viable cellular allografts (VCA) have achieved high clinical utility, but their cost-effectiveness remains uncertain. Granular cost analyses are needed to clarify how graft selection influences expenditures and outcomes.
Methods:
Adults aged 18 to 89 years undergoing primary 1- to 2-level lumbar interbody fusion between March 2015 and July 2023 for degenerative pathology were included. Itemized procedural supplies were priced in 2023 USD, and operating room (OR) time was valued using a standardized cost per minute. Pareto analysis summarized cost domains. Multivariable linear, logistic, and Cox regression models were adjusted for demographics, diagnosis, surgeon, approach, level(s), fixation, laminectomy, and operative duration.
Results:
Among 955 cases, 111 (11.6%) used iliac crest bone graft (ICBG), 257 (26.9%) local autograft, 263 (27.5%) VCA, and 324 (33.9%) BMP. OR time, interbody devices, grafts, and fixation accounted for 95% of the total direct procedural cost. Grafting exhibited the widest interquartile cost range ($3200). Median total procedural costs were significantly higher (adjusted P <0.001-0.005) for VCA (1 level: $16,949; 2 level: $24,424) and BMP ($14,654; $26,193) compared with ICBG ($14,093; $17,757) and local autograft ($11,962; $18,352). Inpatient opioid use, length of stay, 90-day complications, readmissions, revisions, and postoperative Oswestry disability index and EuroQol-5D scores were comparable across groups (adjusted P >0.05).
Conclusions:
Most direct procedural cost concentrated in OR time, interbody devices, and grafts. BMP and VCA markedly increased intraoperative expenditures without measurable improvement in outcomes. Autologous grafting demonstrated the most favorable cost-value profile.
Level Of Evidence:
Level III.
Related Concept Videos
02:45Nuclear Fusion
A helium nucleus has a mass that is 0.7% less than that of four hydrogen nuclei; this lost mass is converted into energy during the fusion. This reaction produces about...
02:24Predicting Reaction Outcomes
01:13Outcomes of Glycolysis
Cellular respiration can occur aerobically (with oxygen) or anaerobically (without oxygen). In the presence of oxygen, cellular respiration starts with glycolysis and continues with pyruvate...
01:11Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
01:24Tagging and Fusion Proteins
01:43SNAREs and Membrane Fusion
SNAREs exist in pairs that symmetrically interact and catalyze the fusion of the lipid bilayers in vesicle and target organelle. v-SNARE in the vesicle membrane are single polypeptide chains that bind to a complementary t-SNARE, composed of 2...